Sinovac Biotech Reports $59.7M Net Loss for 2025, $202.8M Impairments, and $3.3B Special Dividend

summarizeSummary

Sinovac Biotech reported a $59.7 million net loss for 2025, including $202.8 million in impairment charges, and disclosed a $3.3 billion special cash dividend, intensifying concerns amid its Nasdaq delisting threat.

check_boxKey Events

• Significant Net Loss Reported

  The company reported a net loss attributable to common shareholders of $59.7 million for the full year 2025, a substantial decline from a net income of $90.9 million in 2024.

• Massive Impairment Charges

  Sinovac recorded $202.8 million in impairment charges for 2025, including $137.6 million for property, plant, and equipment, and $65.5 million for in-process R&D and goodwill.

• Increased Cash Burn from Operations

  Net cash used in operating activities surged to $512.2 million in 2025, up from $56.9 million in 2024, indicating a significant increase in operational cash outflow.

• Large Special Cash Dividend Paid

  A special cash dividend of $55.00 per common share, totaling $3.96 billion, was declared in April 2025, with $3.3 billion paid out in 2025, representing a massive capital outflow.

auto_awesomeAnalysis

This filing details Sinovac's audited 2025 financial results, revealing a significant swing to a $59.7 million net loss and over $200 million in impairment charges, alongside a substantial increase in cash used in operations. These results are critical given the company's recent Nasdaq delisting notice for failing to file its annual report and previous financial restatements. The declaration and payment of a $3.3 billion special cash dividend in 2025, while beneficial to shareholders, represents a massive outflow of capital for a company reporting losses and facing compliance issues, raising questions about its long-term financial stability.